CD45 EpCAM Antibody Detection for CTC Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting Circulating Tumor Cells (CTCs) in peripheral blood are hindered by large sampling volumes, low sensitivity, poor specificity, and cumbersome operations, making it difficult to accurately identify and isolate these cells for effective cancer screening and diagnosis.
Innovation Solution
A composition comprising anti-CD45 and anti-EpCAM antibodies is used to detect and isolate a cell population co-expressing CD45 and EpCAM from peripheral blood mononuclear cells, utilizing magnetic beads for enrichment and flow cytometry for detection, allowing for efficient cancer screening and treatment guidance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional CTC detection methods are used, then CTCs can be detected, but the sampling volume is large and the operation is cumbersome
Solution Approach 1:
The invention segments the CTC detection process into two distinct steps: first, enrichment of CD45+EpCAM+ cells using magnetic beads; second, detection using flow cytometry. This segmentation allows each step to be optimized independently, reducing overall operational complexity while maintaining high sensitivity for CTC detection.
Solution Approach 2:
The invention extracts and isolates the specific cell population of interest (CD45+EpCAM+ cells) from the complex peripheral blood mononuclear cell mixture using magnetic beads conjugated with anti-CD45 and anti-EpCAM antibodies. This extraction step concentrates the target cells, enabling sensitive detection with smaller sampling volumes and simpler operations.
2Measurement precision
If conventional CTC enrichment methods are used, then tumor cells can be enriched, but the sampling volume is large
Solution Approach 1:
The invention changes the detection parameters by targeting cells that co-express CD45 and EpCAM, which are specific markers for a particular subset of tumor cells. This parameter change allows for more efficient enrichment and detection, reducing the required sampling volume while maintaining high sensitivity for identifying cancer patients.
3Measurement precision
If conventional CTC detection methods are used, then CTCs can be identified, but the specificity is poor
Solution Approach 1:
The invention applies local quality by using dual-specificity antibodies (anti-CD45 and anti-EpCAM) that target specific markers on the surface of tumor cells. This localized targeting approach ensures that only cells with both CD45 and EpCAM markers are enriched and detected, significantly improving the specificity of the test while maintaining high sensitivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method reduces sampling volume, simplifies operations, and enhances sensitivity, enabling rapid and cost-effective in vitro screening and diagnosis of cancer, with a higher sensitivity than existing CTC detection methods, particularly for lung cancer.
Implementation Method 1
adding magnetic beads to the mixture, and incubating the mixture to obtain magnetic beads bound to a cell population co-expressing CD45 and EpCAM
Implementation Method 2
A composition comprising an anti-CD45 antibody and an anti-EpCAM antibody is used to detect and isolate a cell population co-expressing CD45 and EpCAM
Data Source
AI summary
The present invention relates to a method for detecting and isolating a cell population co-expressing CD45 and EpCAM and the use thereof. In the present invention, a composition or a kit comprising an anti-CD45 antibody and an anti-EpCAM antibody is used for detecting and isolating a cell population co-expressing CD45 and EpCAM from PBMCs, and is used for rapid in-vitro screening of cancer, guiding treatment of cancer, and evaluating the effectiveness of cancer treatment.